IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in CareDx, Inc. $CDNA

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in CareDx, Inc. (NASDAQ:CDNA) by 79.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,262 shares of the company’s stock after acquiring an additional 25,880 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.11% of CareDx worth $847,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in CDNA. Next Century Growth Investors LLC boosted its position in shares of CareDx by 309.4% in the 2nd quarter. Next Century Growth Investors LLC now owns 1,125,454 shares of the company’s stock worth $21,991,000 after purchasing an additional 850,580 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in CareDx by 40.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,740,064 shares of the company’s stock valued at $25,301,000 after buying an additional 503,136 shares during the last quarter. SG Capital Management LLC acquired a new stake in CareDx in the second quarter worth about $6,171,000. Ophir Asset Management Pty Ltd grew its stake in shares of CareDx by 17.0% during the second quarter. Ophir Asset Management Pty Ltd now owns 1,892,994 shares of the company’s stock worth $36,989,000 after acquiring an additional 274,625 shares during the last quarter. Finally, Bamco Inc. NY increased its holdings in shares of CareDx by 11.2% during the second quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after acquiring an additional 245,651 shares in the last quarter.

CareDx Price Performance

Shares of NASDAQ CDNA opened at $19.47 on Friday. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of 16.36 and a beta of 2.51. The firm’s 50 day simple moving average is $19.56 and its 200-day simple moving average is $16.11. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $25.55.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.15. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The firm had revenue of $100.06 million for the quarter, compared to the consensus estimate of $95.25 million. During the same period in the prior year, the firm posted ($0.14) earnings per share. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. Analysts anticipate that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on CDNA. Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. BTIG Research raised their price target on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Wells Fargo & Company boosted their price objective on shares of CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Craig Hallum downgraded CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price on the stock. in a research report on Tuesday, January 6th. Finally, Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $26.67.

Insider Buying and Selling at CareDx

In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the transaction, the chief executive officer owned 597,405 shares of the company’s stock, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 29,636 shares of company stock valued at $625,949. 4.40% of the stock is owned by insiders.

CareDx Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.